ProfileGDS5678 / 1441728_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 40% 40% 40% 39% 39% 41% 39% 39% 39% 42% 40% 39% 39% 40% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.948240
GSM967853U87-EV human glioblastoma xenograft - Control 22.9167440
GSM967854U87-EV human glioblastoma xenograft - Control 32.9186140
GSM967855U87-EV human glioblastoma xenograft - Control 42.8459439
GSM967856U87-EV human glioblastoma xenograft - Control 52.8509539
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0361441
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9624739
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8896939
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8599939
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9427242
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9039240
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8632339
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9091139
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9100740